Oncology
Refine Search
Biotechnology
Boston, USA-based Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell-based cellular therapies, is $62 million richer. 7 February 2023
Biotechnology
US pharma major Bristol Myers Squibb has pulled put of a license and collaboration deal with privately-held USA-based biotech Dragonfly Therapeutics. 7 February 2023
Biosimilars
The American business of South Korea's Celltrion Healthcare has appointed Thomas Nusbickel as chief commercial officer. 7 February 2023
Biotechnology
US pharma giant Merck & Co has announced the results of its Phase III NRG-GY018 trial evaluating Keytruda (pembrolizumab) alongside standard-of-care chemotherapy (carboplatin and paclitaxel). 6 February 2023
Pharmaceutical
Shares of US drug developer Context Therapeutics were up more than 7% at $0.97 pre-market, after it announced that two patients enrolled in the Phase II OATH trial of ONA-XR plus anastrozole in advanced endometrial cancer) have achieved partial response (tumor shrinkage) to the treatment. 6 February 2023
Biosimilars
Sandoz, the generics and biosimilars business unit of Swiss pharma giant Novartis that is soon to be spun out, today announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for proposed biosimilar denosumab. 6 February 2023
Biotechnology
Gilead Sciences’ shares closed up 3.8% at $84.50 on Friday, after the US biotech major revealed a new US regulatory approval for one of its core growth drivers in the cancer setting. 4 February 2023
Biotechnology
Shares in Gilead Sciences were up by more than 4% in Friday’s pre-market trading. 3 February 2023
Pharmaceutical
Shares in US pharma giant Merck & Co were down by more than 3% at lunchtime Thursday after the company presented its latest financial results. 3 February 2023
Pharmaceutical
French privately-held pharma company Servier has announced its financial results for the 2021/22 financial year, highlighting the major steps of its ongoing transformation. 3 February 2023
Pharmaceutical
US drugmaker Bristol Myers Squibb was trading 2% higher at lunchtime Thursday after presenting its fourth quarter and full year 2022 financial results. 2 February 2023
Biotechnology
Israel-based clinical-stage company Purple Biotech saw its shares gains 9.5% to 61.00 shekels today, as announced that it has entered into an agreement to acquire Netherlands-headquartered, venture capital backed Immunorizon. 2 February 2023
Pharmaceutical
USA-based Eli Lilly has announced revenues of $7.3 billion in the final quarter of 2022, a 9% decrease from the same period of last year, around what most analysts had anticipated. 2 February 2023
Pharmaceutical
Roche’s shares dipped 1.4% to 322.60 francs this morning, when the Swiss pharma giant announced that, in full-year 2022, it achieved sales growth of 2% (+1% in Swiss francs) to 63.3 billion francs ($.66.8 billion), but warned that 2023 profits would see a downturn. 2 February 2023
Biotechnology
Canadian mRNA-focussed biotech firm Providence Therapeutics today announced the appointment of Robert Georgantas III as president and chief technology officer (CTO). 1 February 2023
Biotechnology
UK-based Orbit Discovery, which calls itself a ‘leader in the discovery of therapeutic peptide hits’, has announced a collaboration. 1 February 2023
Pharmaceutical
British pharma major GSK outperformed expectations with its annual financial results statement, reporting sales of £29.3 billion ($36.1 billion) for the year, an increase of 19%, driven by revenues of £7.4 billion in the final quarter. 1 February 2023
Biotechnology
US biotech giant Amgen released mixed financial results for the fourth quarter and full year 2022 versus comparable periods in 2021, after markets closed on Monday. 1 February 2023
Pharmaceutical
US drugmaker Pfizer cemented its place at the top of the pile of global pharma companies in delivering its 2022 financial results. 31 January 2023
Pharmaceutical
The Belgian pharmaceutical industry has raised concerns around pressures being applied to the national healthcare budget for innovative medicines. 30 January 2023
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze